Table 1.

Patient characteristics

Total patients	(n = 36)
Age, median (IQR), years	63 (10)
Tumor classification
cT1	27 (75.0%)
cT2	9 (25.0%)
Gleason Score
3-5	8 (22.2%)
6	23 (63.9%)
7	5 (13.9%)
Pre-treatment PSA
≤10 ng/mL	31 (86.1%)
>10 ng/mL	5 (13.9%)
Percent positive biopsies
≤ 50%	17 (47.2%)
> 50%	14 (38.9%)
Unknown	5 (13.9%)
Risk group
Low	28 (77.8%)
Intermediate	8 (22.2%)

Abbreviations: PSA prostate-specific antigen, IQR interquartile range.